literature & papers


Zahn et al. 2023 – Metabolites
Targeting Longevity Gene SLC13A5: A Novel Approach to Prevent Age-Related Bone Fragility and Osteoporosis


Sandforth et al. 2023 – The Lancet Diabetes & Endocrinology
Mechanisms of weight loss-induced remission in people with prediabetes: a post-hoc analysis of the randomised, controlled, multicentre Prediabetes Lifestyle Intervention Study (PLIS)


Gill et al. 2023 – BMC medicine
The citrate transporter SLC13A5 as a therapeutic target for kidney disease: evidence from Mendelian randomization to inform drug development


Zahn et al. 2022 – Metabolites
A Novel and Cross-Species Active Mammalian INDY (NaCT) Inhibitor Ameliorates Hepatic Steatosis in Mice with Diet-Induced Obesity


Pesta and Jordan 2022 – Metabolites
INDY as a Therapeutic Target for Cardio-Metabolic Disease


Sandforth et al. 2022 – J Hepatol
Is NAFLD a Key Driver of Brain Dysfunction?


 Wagner et al. 2021 – Nature Medicine
Pathophysiology-based subphenotyping of individuals at elevated risk for type 2 diabetes


Henke et al. 2020 – Neurobiol Dis
Disruption of the sodium-dependent citrate transporter SLC13A5 in mice causes alterations in brain citrate levels and neuronal network excitability in the hippocampus


Schumann et al. 2020 – Pharmacology Review
Solute Carrier Transporters as Potential Targets for the Treatment of Metabolic Disease


Parhofer et al. 2019 – ExpClin Endocrinol Diabetes
Position Paper on Lipid Therapy in Patients with Diabetes Mellitus.


Angelini et al. 2019 – Sci Rep
New insight into the mechanisms of ectopic fat deposition improvement after bariatric surgery.


Angelini et al. 2019 – Sci Rep
New insight into the mechanisms of ectopic fat deposition improvement after bariatric surgery.


Husain et al. 2019 – NEJM
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.


El-Agroudy et al. 2019 – Cell Metabolism
Are Lifestyle Therapies Effective for NAFLD Treatment?


Reuter and Jordan 2019 – Curr Opin Cardiol
Status of hypertension in Europe.


Selch et al. – 2018 Sci Rep
Analysis of naturally occurring mutations in the human uptake transporter NaCT important for bone and brain development and energy metabolism.


Jordan et al. 2018 – Hypertension
Natriuretic Peptides in Cardiovascular and Metabolic Crosstalk: Implications for Hypertension Management.


Willmes et al. 2018 – Pharmacol Ther.
Review: The longevity gene INDY (I’m Not Dead Yet) in metabolic control: Potential as pharmacological target


von Loeffelholz et al. 2017 – Hepatology
The Human Longevity Gene Homolog INDY and Interleukin-6 Interact in Hepatic Lipid Metabolism


Brachs et al. 2016 – Molecular Metabolism
Inhibition of citrate cotransporter Slc13a5/mINDY by RNAi improves hepatic insulin sensitivity and prevents diet-induced non-alcoholic fatty liver disease in mice


Willmes et al. 2016 – Aging
The longevity transporter mIndy (Slc13a5) as a target for treating hepatic steatosis and insulin resistance


Jordan and Birkenfeld 2016 – Rev Endocr Metab Disord
Cardiometabolic crosstalk in obesity-associated arterial hypertension


Jordan et al. 2015 – J Hypertension
Joint scientific statement of the European Association for the Study of Obesity and the European Society of Hypertension: Obesity and early vascular ageing.


Neuschaefer-Rube et al. 2015 – Toxicology
Arylhydrocarbon receptor (AhR) dependent mIndy (Slc13a5) induction as possible contributor to benzo[a]pyrene induced lipid accumulation in hepatocytes


Schwarz et al. 2015 – Aging
Knockdown of Indy/CeNac2 extends Caenorhabditis elegans life span by inducing AMPK/aak‐2.


Pesta et al. 2015 – Aging
Prevention of diet‐induced hepatic steatosis and hepatic insulin resistance by second generation antisense oligonucleotides targeted to the longevity gene mIndy (Slc13a5).


Neuschaefer-Rube et al. 2013 – Diabetes
The Mammalian INDY Homolog is Induced by cAMP responsive-element-binding protein (CREB) in a Rat Model of Type 2 Diabetes.


Willmes and Birkenfeld 2013 – Comp Struct Biotech J
The Role of INDY in Metabolic Regulation (Review)


Birkenfeld et al. 2011 – Cell Metab
Deletion of the Mammalian INDY Homolog Mimics Aspects of Dietary Restriction and Protects against Adiposity and Insulin Resistance in Mice.

Chen et al. 2023 Metabolites.
Mapping the Metabolic Niche of Citrate Metabolism and SLC13A5.


Dirckx et al. 2022 PNAS.
A specialized metabolic pathway partitions citrate in hydroxyapatite to impact mineralization of bones and teeth.


Kopel et al. 2021 Biochem J.
Consequences of NaCT/SLC13A5/mINDY deficiency: good versus evil, separated only by the blood-brain barrier.


Kopel et al. 2021 Psychatric Genetics.
Metformin, valproic acid, and starvation induce seizures in a patient with partial SLC13A5 deficiency: a case of pharmaco-synergistic heterozygosity.


Sauer et al. 2021 Nature.
Structure and inhibition mechanism of the human citrate transporter NaCT.


Hu et al. 2020 – Toxicol App Pharmacol
Comparative proteomic analysis of SLC13A5 knockdown reveals elevated ketogenesis and enhanced cellular toxic response to chemotherapeutic agents in HepG2 cells.


Kopel et al. 2020 – Sci Rep
The Hepatic Plasma Membrane Citrate Transporter NaCT (SLC13A5) as a Molecular Target for Metformin.


Poolsri et al. 2018 – Biomed Res Int
Combination of Mitochondrial and Plasma Membrane Citrate Transporter Inhibitors Inhibits De Novo Lipogenesis Pathway and Triggers Apoptosis in Hepatocellular Carcinoma Cells.


Phokrai et al. 2018 – FEBS Open Bio
Suppressed de novo lipogenesis by plasma membrane citrate transporter inhibitor promotes apoptosis in HepG2 cells.


Peters 2017 – J Biol. Chem
Flipping a citrate switch on liver cancer cells.


Li et al. 2017 – J Biol Chem
Silencing of solute carrier family 13 member 5 disrupts energy homeostasis and inhibits proliferation of human hepatocarcinoma cells


Rogina 2017 – Frontiers in Genetics
INDY-A New Link to Metabolic Regulation in Animals and Humans


Pajor et al. 2016 – Molecular Pharmacology
Molecular Basis for Inhibition of the Na+/Citrate Transporter NaCT (SLC13A5) by Dicarboxylate Inhibitors


Rives et al. 2016 – Molecular Pharmacology
State-Dependent Allosteric Inhibition of the Human SLC13A5 Citrate Transporter by Hydroxysuccinic Acids, PF-06649298 and PF-06761281


Huard et al. 2016 – J Med Chem
Optimization of a Dicarboxylic Series for in Vivo Inhibition of Citrate Transport by the Solute Carrier 13 (SLC13) Family


Huard et al. 2015 – Sci Rep
Discovery and characterization of novel inhibitors of the sodium-coupled citrate transporter (NaCT or SLC13A5)


Hardies et al. 2015 – Brain
Recessive mutations in SLC13A5 result in a loss of citrate transport and cause neonatal epilepsy, developmental delay and teeth hypoplasia


Gopal et al. 2015 – J Pharmacol Exp Ther
Species-specific Influence of Lithium on the Activity of SLC13A5 (NaCT): Lithium-induced Activation is Specific for the Transporter in Primates.


Mancusso et al. 2012 – Nature
Structure and mechanism of a bacterial sodium-dependent dicarboxylate transporter (crystal structure of vcINDY, a bacterial homologue of INDY, NaCT).


Gopal et al. 2007 – Am J Physiol Gastrointest Liver Physiol
Expression and functional features of NaCT, a sodium-coupled citrate transporter, in human and rat livers and cell lines.


Inoue et al. 2002 – Biochem Biophys Res Comm
Human Na+-coupled citrate transporter (NaCT): primary structure, genomic organization, and transport function.


Rogina et al. 2000 – Science
Extended Life-Span Conferred by Cotransporter Gene Mutations in Drosophila (discovery of INDY: I am Not Dead Yet).